Skip Navigation

Nephrology Dialysis Transplantation 2005 20(Supplement 8):viii8-viii12; doi:10.1093/ndt/gfh1110
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Campise, M.
Right arrow Articles by Collins, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Campise, M.
Right arrow Articles by Collins, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Impact of pre-transplant anaemia correction and erythropoietin resistance on long-term graft survival

Mariarosaria Campise1, Ashraf Mikhail2, Thomas Quaschning3, Jon Snyder4 and Allan Collins4

1 UO Nefrologia, IRCCS Ospedale Maggiore, Milano, Italy, 2 Department of Renal Medicine, Morriston Hospital, Swansea, UK, 3 Department of Internal Medicine, Division of Nephrology and Hypertension, University Hospital Würzburg, Würzburg, Germany and 4 USRDS, University of Minnesota, Minneapolis, USA

Correspondence and offprint requests to: Mariarosaria Campise, MD, UO Nefrologia, IRCCS Ospedale Maggiore, Via Commenda, 15, 20122 Milano, Italy. Email: campise{at}policlinico.mi.it

Background. This study investigated whether recombinant human erythropoietin (rHuEPO)-hyporesponsive anaemia before transplantation is associated with a poorer graft outcome and lower patient survival.

Methods. A total of 15 051 kidney transplant recipients, with a minimum follow-up of 1 year, were stratified as either rHuEPO hyporesponsive or rHuEPO responsive (using a threshold rHuEPO-treated haemoglobin level of 11 g/dl). They were followed for a median of 24 months. Outcomes included times from transplantation to graft failure (including patient death), return to dialysis or pre-emptive re-transplantation, and death with a functioning graft.

Results. The cumulative incidence of graft failure was 50% for rHuEPO-hyporesponsive patients, compared with 41.7% for rHuEPO responders (P = 0.0091). Among rHuEPO-hyporesponsive patients, 41.7% returned to dialysis or underwent a pre-emptive re-transplantation, compared with 32% of rHuEPO responders (P = 0.0091). Death with a functioning graft occurred in 16.9% of rHuEPO-hyporesponsive and in 15% of rHuEPO-responsive patients (P = 0.3949).

Conclusions. The results showed higher mortality and higher incidence of graft failure at 5 years for rHuEPO-hyporesponsive patients. It is unclear whether anaemia treatment per se or treatment of more severe co-morbidity resulting in hyporesponsiveness to anaemia treatment may be causally linked to reduced renal transplant outcomes.

Keywords: aggressive treatment; anaemia; graft failure; patient survival; post-transplant patients; rHuEPO hyporesponsiveness


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.